Detalhe da pesquisa
1.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
2.
A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Blood
; 135(15): 1232-1243, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32040549
3.
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 31(3): 760-8, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22907596
4.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Lancet Oncol
; 12(8): 773-84, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21724462
5.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749004
6.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Blood
; 114(8): 1489-97, 2009 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19498019
7.
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Blood Adv
; 4(18): 4538-4549, 2020 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32956453
8.
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Blood Adv
; 4(5): 906-919, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32150609
9.
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Clin Cancer Res
; 14(20): 6656-62, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18927308
10.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Blood Adv
; 7(4): 644-648, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36006441
11.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913648
12.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
J Clin Oncol
; 23(17): 3912-22, 2005 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15851766
13.
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Int J Radiat Oncol Biol Phys
; 63(5): 1400-12, 2005 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16005577
14.
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Cancer Chemother Pharmacol
; 74(5): 955-67, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25183650
15.
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Clin Cancer Res
; 19(15): 4262-72, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23741066
16.
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Clin Cancer Res
; 19(9): 2551-61, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549871
17.
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
J Hematol Oncol
; 5: 67, 2012 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23088650
18.
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Cancer J
; 15(5): 395-400, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19826359
19.
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
J Clin Oncol
; 27(25): 4188-96, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19652065
20.
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 63(1): 181-8, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18379785